ライフサイエンスコーパス: hemorrhagic stroke

1 ow promise for the treatment of ischemic and hemorrhagic stroke.

2 readmission, cardiovascular readmission, and hemorrhagic stroke.

3 ic stroke, and 0.80 (95% CI: 0.61, 1.04) for hemorrhagic stroke.

4 ll alive with 1 death on ECMO, attributed to hemorrhagic stroke.

5 d ischemic stroke and 229 (2.2%) experienced hemorrhagic stroke.

6 hould not aggravate outcomes associated with hemorrhagic stroke.

7 e debilitating ischemia and life-threatening hemorrhagic stroke.

8 95% CI, 0.41-0.57) per 1000 person-years for hemorrhagic stroke.

9 impact of TSC in rat models of ischemic and hemorrhagic stroke.

10 in experimental models of both ischemic and hemorrhagic stroke.

11 hat tend to rupture, increasing the risk for hemorrhagic stroke.

12 centrations were not associated with risk of hemorrhagic stroke.

13 ety and feasibility of early BP reduction in hemorrhagic stroke.

14 disorders, including myopathy, glaucoma and hemorrhagic stroke.

15 formations (bAVMs) are an important cause of hemorrhagic stroke.

16 ation in the brain that are a major cause of hemorrhagic stroke.

17 apillaries, leading to headache, seizure and hemorrhagic stroke.

18 , 1.18 (1.06-1.31), and 1.54 (1.27-1.87) for hemorrhagic stroke.

19 ents a promising neuroprotective strategy in hemorrhagic stroke.

20 scular abnormalities that cause seizures and hemorrhagic stroke.

21 f future therapeutic interventions following hemorrhagic stroke.

22 participants with incident strokes; 14% had hemorrhagic stroke.

23 ight striatum to mimic the natural events of hemorrhagic stroke.

24 tudy of the pathophysiology and treatment of hemorrhagic stroke.

25 investigating the complex pathophysiology of hemorrhagic stroke.

26 e prone to rupture, resulting in seizures or hemorrhagic stroke.

27 ary GL was associated with a greater risk of hemorrhagic stroke.

28 ed number of patients with liver disease and hemorrhagic stroke.

29 uggest that CEE had an effect on the risk of hemorrhagic stroke.

30 or ischemic stroke and 0.64 (0.35, 1.18) for hemorrhagic stroke.

31 ve been associated with an increased risk of hemorrhagic stroke.

32 was associated with lower risk of total and hemorrhagic stroke.

33 or for total and ischemic stroke but not for hemorrhagic stroke.

34 ed to the end of 1998 for thromboembolic and hemorrhagic stroke.

35 n shown to play a role in the progression of hemorrhagic stroke.

36 relationship between alcohol consumption and hemorrhagic stroke.

37 emonstrated opposing effects on ischemic and hemorrhagic stroke.

38 verall stroke rate by half and did not cause hemorrhagic stroke.

39 emic stroke and 1.36 (95% CI, 0.48-3.82) for hemorrhagic stroke.

40 r long-chain omega-3 PUFA intake and risk of hemorrhagic stroke.

41 rin regularly, but is not related to risk of hemorrhagic stroke.

42 olyunsaturated fatty acid intake and risk of hemorrhagic stroke.

43 and rupture of the vessel wall, resulting in hemorrhagic stroke.

44 e cerebral vessel wall and, in severe cases, hemorrhagic stroke.

45 t was found for ischemic stroke, but not for hemorrhagic stroke.

46 ith separate analyses of ischemic stroke and hemorrhagic stroke.

47 bilities, including intractable seizures and hemorrhagic stroke.

48 association between alcohol consumption and hemorrhagic stroke.

49 mortality rate was 26% in the 2 weeks after hemorrhagic stroke.

50 e that aspirin therapy increases the risk of hemorrhagic stroke.

51 studies have suggested it increases risk of hemorrhagic stroke.

52 actors for ischemic and total stroke but not hemorrhagic stroke.

53 stress in cancer, heat stress in plants, and hemorrhagic stroke.

54 ess the effect of alirocumab on ischemic and hemorrhagic stroke.

55 cortical or vertebrobasilar, and ischemic or hemorrhagic stroke.

56 rebral circulation, resulting in ischemic or hemorrhagic stroke.

57 L-C levels and a potential increased risk of hemorrhagic stroke.

58 ndidate agents for this untreatable cause of hemorrhagic stroke.

59 the mechanism and predictors of ischemic and hemorrhagic stroke.

60 any stroke: 166 of ischemic stroke and 55 of hemorrhagic stroke.

61 n of ischemic injury, and presumed perinatal hemorrhagic stroke.

62 ted with increased risk of stroke overall or hemorrhagic stroke.

63 associated factors, and outcomes of neonatal hemorrhagic stroke.

64 target molecule to limit brain damage during hemorrhagic stroke.

65 positive for ischemic stroke and inverse for hemorrhagic stroke.

66 hemic stroke), and 5 were presumed perinatal hemorrhagic stroke.

67 , seizures, focal neurological deficits, and hemorrhagic stroke.

68 and 0.2% (95% CI = 0.1-0.3%, I(2) = 64%) for hemorrhagic stroke.

69 th an increased risk of stroke, particularly hemorrhagic stroke.

70 p = 0.02) were independently associated with hemorrhagic stroke.

71 ischemic stroke; and HR 1.53 (0.91-2.59) for hemorrhagic stroke.

72 increased fatal and nonfatal GI bleeding and hemorrhagic stroke.

73 (IS), 15% transient ischemic attacks, and 9% hemorrhagic strokes.

74 e vascular inflammation leading to recurrent hemorrhagic strokes.

75 ersons and can be complicated by ischemic or hemorrhagic strokes.

76 n HCHWA-D, lead to recurrent and often fatal hemorrhagic strokes.

77 spirin increase gastrointestinal bleeding or hemorrhagic strokes?

78 nts/patient-year) were higher than those for hemorrhagic stroke (0.05), ischemic stroke (0.04), and p

79 infections (0.47 versus 0.27, P<0.001), and hemorrhagic stroke (0.07 versus 0.03, P=0.01).

80 Among HRT users and non-users, the rates of hemorrhagic stroke (0.40% vs. 0.42%, p = 1.00) and ische

81 .00), ischemic stroke (0.67; 0.48-0.93), and hemorrhagic stroke (0.45; 0.45-0.99) versus rivaroxaban.

82 4; P=0.008) and a nonsignificant increase in hemorrhagic stroke (0.8% versus 0.6%; HR, 1.38; 95% CI,

83 the Watchman device had significantly fewer hemorrhagic strokes (0.15 vs. 0.96 events/100 patient-ye

84 stroke was 1.44 (95% CI, 1.09-1.90) and for hemorrhagic stroke, 0.82 (95% CI, 0.43-1.56).

85 rson-years; p < 0.001) and the incidences of hemorrhagic stroke (1.21 vs. 4.19 events per 1000 person

86 aining phenylpropanolamine and the risk of a hemorrhagic stroke, 1.23 (95 percent confidence interval

87 vated protein C-treated patients (0.25%) had hemorrhagic stroke, 107 (6.8%) had gastrointestinal blee

88 cident ischemic stroke and 140 with incident hemorrhagic stroke (18 participants had both during the

89 chemic stroke, 1.69 (95% CI, 1.34-2.15); and hemorrhagic stroke, 2.18 (95% CI, 1.48-3.20), while cons

90 uses of death were multiorgan failure (26%), hemorrhagic stroke (24%), and progressive heart failure

91 s; summary RR: 1.13; 95% CI: 0.99, 1.28), or hemorrhagic stroke (3 cohorts; summary RR: 1.09; 95% CI:

92 with patients without a stroke (43+/-12% for hemorrhagic stroke, 57+/-9% for ischemic stroke, 51+/-11

93 The mortality rate was higher for hemorrhagic stroke (68%) than for ischemic stroke (57%).

94 den death (9 vs. 3), and bleeding, including hemorrhagic stroke (7 vs. 2).

95 I: 0.53, 1.34; P-trend = 0.44), and 0.75 for hemorrhagic stroke (95% CI: 0.32, 1.77; P-trend = 0.40).

96 h retinal vein occlusion had higher risks of hemorrhagic stroke (adjusted HR, 2.54 [95% CI, 1.50-4.30

97 2003, amphetamine abuse was associated with hemorrhagic stroke (adjusted odds ratio [OR], 4.95; 95%

98 ence interval [CI], 0.48-0.82); 9 and 19 had hemorrhagic strokes (adjusted RR, 0.46; 95% CI, 0.21-1.0

99 data from 204 591 patients with ischemic and hemorrhagic stroke admitted to 1563 Get With the Guideli

100 In addition to its role in hemorrhagic stroke, advanced cerebral amyloid angiopathy

101 The delayed timing of major and hemorrhagic stroke after revascularization suggests that

102 of AMI, and women are at increased risk for hemorrhagic stroke after thrombolytic therapy.

103 hemic stroke (aHR = 2.03, P = .003), but not hemorrhagic stroke (aHR = 1.24, P = .696), than the cont

104 9; 95% confidence interval [CI], 1.40-1.80), hemorrhagic stroke (aHR, 2.37; 95% CI, 1.90-2.96), myoca

105 6, 1.77]), while a negative association with hemorrhagic stroke also appeared within this subgroup.

106 r ischemic stroke, and 1.35 [1.13, 1.61] for hemorrhagic stroke among men, while among women higher a

107 d 10,922 ischemic strokes, and 2492 and 2363 hemorrhagic strokes among men and women, respectively.

108 on both stroke subtypes (1.66; 1.39-1.98 for hemorrhagic stroke and 1.63; 1.57-1.69 for ischemic stro

109 aining phenylpropanolamine and the risk of a hemorrhagic stroke and 3.13 (95 percent confidence inter

110 myloid angiopathy [CAA]) is a major cause of hemorrhagic stroke and a likely contributor to vascular

111 are most sensitive to the relative risk for hemorrhagic stroke and CVD mortality but are affected by

112 Excess risk for hemorrhagic stroke and gastrointestinal bleeding with as

113 of arterial vessels, has been implicated in hemorrhagic stroke and is present in most cases of Alzhe

114 The 2 fundamental subtypes of stroke are hemorrhagic stroke and ischemic stroke.

115 Using a rodent model of hemorrhagic stroke and next-generation proteomic and met

116 g BID) compared with rivaroxaban, as well as hemorrhagic stroke and nondisabling stroke.

117 otentially useful treatment in patients with hemorrhagic stroke and perhaps other acute brain injurie

118 ns for impairment of consciousness following hemorrhagic stroke and recovery at ICU discharge.

119 iety of neurological disabilities, including hemorrhagic stroke and seizures.

120 d conditions such as traumatic brain injury, hemorrhagic stroke and uncontrolled surgical bleeding.

121 Intracerebral hemorrhagic stroke and vascular dementia are age- and hy

122 yocardial infarctions but would cause 0 to 2 hemorrhagic strokes and 2 to 4 major gastrointestinal bl

123 yocardial infarctions but would cause 0 to 2 hemorrhagic strokes and 2 to 4 major gastrointestinal bl

124 vascular malformations, which may result in hemorrhagic strokes and neurological deficits.

125 Incident strokes, excluding hemorrhagic strokes and strokes of cardiac origin, were

126 roke/transient ischemic attack and 153 prior hemorrhagic stroke) and bleeding (318 prior major bleedi

127 ng death, all-cause stroke, ischemic stroke, hemorrhagic stroke, and bleeding hospitalizations in ESR

128 for myocardial infarction, ischemic stroke, hemorrhagic stroke, and cardiovascular mortality and unt

129 s of being transferred included younger age, hemorrhagic stroke, and higher stroke severity, but havi

130 l reductions in major bleeding, particularly hemorrhagic stroke, and mortality.

131 protective benefits on all-cause mortality, hemorrhagic stroke, and new-onset dialysis in HCV-infect

132 dial infarction (AMI), ischemic stroke (IS), hemorrhagic stroke, and new-onset dialysis were evaluate

133 e menopause and gestational hypertension for hemorrhagic stroke, and oophorectomy, HDP, preterm deliv

134 rdial infarctions, 754 ischemic strokes, 160 hemorrhagic strokes, and 161 other cardiovascular [CV] d

135 ich triggers small-vessel disease, recurrent hemorrhagic strokes, and age-related macroangiopathy.

136 % of the population and accounts for 500,000 hemorrhagic strokes annually in mid-life (median age 50)

137 Ischemic stroke, hemorrhagic stroke, any stroke, and stroke mortality.

138 Excess risk for nonfatal hemorrhagic stroke appeared confined to the 1st year aft

139 ven protective for myocardial infarction and hemorrhagic stroke ( approximately 2-4 drinks: relative

140 High rates of head CT use for patients with hemorrhagic stroke are frequently observed, without an a

141 ortality rates remain high when ischemic and hemorrhagic strokes are present.

142 ther pursued as targets for the treatment of hemorrhagic stroke as adjuvant treatment for stroke pati

143 , the risks of gastrointestinal bleeding and hemorrhagic strokes associated with aspirin use outweigh

144 r recurrence were patients with a history of hemorrhagic stroke before entry into the study (two-year

145 P=0.004), with no difference in the rates of hemorrhagic stroke between the active and placebo arms (

146 atment effect was observed within 1 year for hemorrhagic strokes but was not seen until the second ye

147 The patients were followed for recurrent hemorrhagic stroke by interviews at six-month intervals

148 gulation, LAAC resulted in improved rates of hemorrhagic stroke, cardiovascular/unexplained death, an

149 om 16 trials with 55462 participants and 108 hemorrhagic stroke cases were analyzed.

150 ding transient ischemic attack, ischemic and hemorrhagic stroke, cerebral venous thrombosis, and nons

151 gs significantly increase the probability of hemorrhagic stroke: coma (likelihood ratio [LR], 6.2; 95

152 c stroke, and 0.82 (95% CI 0.43 to 1.58) for hemorrhagic stroke compared with women with BMI <25 kg/m

153 Aside from hemorrhagic stroke, corresponding associations of cardio

154 Furthermore, risk of hemorrhagic stroke did not depend on achieved LDL-C leve

155 However, differences in hemorrhagic stroke, disabling/fatal stroke, cardiovascul

156 and risk of any stroke, ischemic stroke, and hemorrhagic stroke during a mean follow-up interval of 1

157 or nonmajor clinically relevant bleeding and hemorrhagic stroke during treatment.

158 d hemorrhagic (gastrointestinal bleeding and hemorrhagic stroke) events occurring outside of the hosp

159 2) bleeding (composite of readmission due to hemorrhagic stroke, gastrointestinal bleeding, bleeding

160 ial infarction; and of nonfatal ischemic and hemorrhagic stroke) gave an unadjusted relative risk of

161 d Genetic and Environmental Risk Factors for Hemorrhagic Stroke (GERFHS) study.

162 and no controlled trials of hypothermia for hemorrhagic stroke have been performed.

163 ge was not associated with increased risk of hemorrhagic stroke (hazard ratio, 0.94; 95% confidence i

164 receiving the device had significantly fewer hemorrhagic strokes (hazard ratio 0.22, P=0.004); (2) a

165 epatobiliary, and neurocognitive events; and hemorrhagic stroke, heart failure, cancer, and noncardio

166 Bleeding outcome was serious bleeding (hemorrhagic stroke, hospitalization for bleeding, transf

167 0.73 [95% CI, 0.57-0.93]) without increasing hemorrhagic stroke (HR, 0.83 [95% CI, 0.42-1.65]).

168 chemic stroke (HR, 1.11 [1.02-1.21]) but not hemorrhagic stroke (HR, 1.02 [0.82-1.29]).

169 chemic stroke (HR, 1.27; 95% CI, 1.23-1.32), hemorrhagic stroke (HR, 1.36; 95% CI, 1.26-1.46), myocar

170 , ischemic stroke (HR, 1.27; 1.02-1.59), and hemorrhagic stroke (HR, 1.70; 1.01-2.84).

171 n E was associated with an increased risk of hemorrhagic stroke (HR, 1.74 [95% CI, 1.04-2.91]; P = .0

172 y aimed to investigate the long-term risk of hemorrhagic stroke (HS) in patients with infective endoc

173 Hemorrhagic stroke (HS), ie, subarachnoid hemorrhage and

174 e, cerebrovascular disease, ischemic stroke, hemorrhagic stroke, hypertensive heart disease, cardiomy

175 kely to be older, smokers, have a history of hemorrhagic stroke, hypothyroidism, and dementia, and le

176 ibrillation, and document the lowest rate of hemorrhagic stroke identified in this population.

177 mic stroke in 3 patients (1.7% per year) and hemorrhagic stroke in 1 patient (0.6% per year).

178 performed for elderly patients admitted for hemorrhagic stroke in 2008-2009, with 1-year follow-up t

179 t ischemic attack (TIA), ischemic stroke, or hemorrhagic stroke in adults aged 18 through 50 years ad

180 nalysis in men showed no increased risk of a hemorrhagic stroke in association with the use of cough

181 in children with SCA without screening), and hemorrhagic stroke in children and adults with SCA (3% a

182 The mortality of hemorrhagic stroke in children is lower than that in adu

183 n young people and contribute to half of all hemorrhagic stroke in children.

184 Ischemic or hemorrhagic stroke in hospitalized and nonhospitalized p

185 coronary heart disease, ischemic stroke, and hemorrhagic stroke in husbands were 1.13 (95% confidence

186 may outweigh its adverse effects on risk of hemorrhagic stroke in most populations.

187 There was no increase in hemorrhagic stroke in patients on pravastatin compared w

188 diagnostic test to distinguish ischemic from hemorrhagic stroke in patients presenting with stroke-li

189 sk factors and outcomes of each ischemic and hemorrhagic stroke in patients with venoarterial extraco

190 ivating blood vessels, prevents ischemic and hemorrhagic stroke in spontaneously hypertensive, geneti

191 Conversely, the incidence of hemorrhagic stroke in SS patients was highest among pati

192 onstrated a higher risk of both ischemic and hemorrhagic stroke in subjects with COPD and revealed th

193 etween lower achieved LDL-C and incidence of hemorrhagic stroke in the alirocumab group.

194 nited States because of an increased risk of hemorrhagic stroke in women.

195 remedies, is an independent risk factor for hemorrhagic stroke in women.

196 Fs, 3262 MIs, 2039 ischemic strokes, and 405 hemorrhagic strokes in men and 1207 HFs, 1504 MIs, 1561

197 There was a tendency toward more major hemorrhagic strokes in symptomatic than in asymptomatic

198 d, beyond 30 days, to the occurrence of more hemorrhagic strokes in the TAVR group (2.2% vs. 0.6%, P=

199 and meta-analysis suggest that the risk for hemorrhagic strokes in women is not statistically signif

200 Fs, 1504 MIs, 1561 ischemic strokes, and 294 hemorrhagic strokes in women.

201 excess risk of death from ischemic, but not hemorrhagic, stroke in US black children has decreased o

202 BMI increases the risk of both ischemic and hemorrhagic stroke incidence, and stroke mortality in Ch

203 charge diagnosis codes for acute ischemic or hemorrhagic stroke (International Classification of Dise

204 n risk of ischemic stroke without increasing hemorrhagic stroke, irrespective of baseline LDL-C and o

205 Hemorrhagic stroke is a significant cause of morbidity a

206 Neonatal hemorrhagic stroke is more common than previously report

207 This excess risk of hemorrhagic stroke is particularly high in patients rece

208 treatment of ischemic strokes, treatment of hemorrhagic stroke is progressing more slowly.

209 mes were arrhythmia, cerebrovascular events, hemorrhagic stroke, ischemic stroke, coronary revascular

210 Italian kindred who presented with recurrent hemorrhagic strokes late in life, between 60 and 70 year

211 articipants; and occurrences of ischemic and hemorrhagic stroke, major extracranial bleeding, and dea

212 inant ADAMTS13 did not enhance bleeding in a hemorrhagic stroke model.

213 delivering MSCs intraventricularly in a rat hemorrhagic stroke model.

214 protects neurons, and improves behavior in a hemorrhagic stroke model.

215 The ethnic disparity in hemorrhagic stroke mortality, however, remained relative

216 risks (RR) of stroke and systemic embolism, hemorrhagic stroke, myocardial infarction, cardiovascula

217 fluid (CSF) from patients with ischemic and hemorrhagic stroke (n=25) and in contemporary controls (

218 Dietary GL was associated with hemorrhagic stroke [n = 165; relative risk = 1.44 compar

219 The clinical epidemiology of neonatal hemorrhagic stroke (NHS) remains undefined, hindering th

220 All 3 hemorrhagic strokes occurred in the placebo group.

221 kes occurred within 48 hours of PCI, and all hemorrhagic strokes occurred within 48 hours.

222 In total, 263 ischemic and 33 hemorrhagic strokes occurred.

223 MII), 65 strokes (40 ischemic strokes and 25 hemorrhagic strokes) occurred in 52 patients at a median

224 associated with an absolute risk increase in hemorrhagic stroke of 12 events per 10000 persons (95% C

225 f products containing phenylpropanolamine to hemorrhagic stroke, often after the first use of these p

226 the risk of severe complications, including hemorrhagic stroke or death.

227 The primary outcome was ischemic or hemorrhagic stroke or systemic embolism.

228 e examined for the occurrence of ischemic or hemorrhagic stroke or transient ischemic attack either b

229 oembolism (OR, 0.79 [95% CI, 0.67-0.93]) and hemorrhagic stroke (OR, 0.78 [95% CI, 0.62-0.98]).

230 associated with a higher risk of death after hemorrhagic stroke (OR, 2.63; 95% CI, 1.07-6.50).

231 is important to note that NAC did not worsen hemorrhagic stroke outcome, suggesting that it exerts th

232 f myocardial infarction, ischemic stroke, or hemorrhagic stroke over a period of 8 years.

233 a significant reduction in deaths caused by hemorrhagic stroke (P=0.01).

234 much higher hospital mortality rate than non-hemorrhagic stroke patients (53% versus 15%, P<0.001), w

235 Hemorrhagic stroke patients had a much higher hospital m

236 Concentrations of CSF FFAs from ischemic and hemorrhagic stroke patients obtained within 48 h of the

237 At discharge, hemorrhagic stroke patients were more likely to be disab

238 itive impairment and antihypertensives among hemorrhagic stroke patients.

239 ions, for 4 domains affected in ischemic and hemorrhagic stroke patients.

240 endothelial cells of hemorrhagic lesions of hemorrhagic stroke patients.

241 Compared with hemorrhagic stroke, patients with ischemic stroke had hi

242 GI bleeding and 0.32 (CI, -0.05 to 0.82) for hemorrhagic stroke per 1000 person-years of aspirin expo

243 Because of its potential association with hemorrhagic strokes, phenylpropanolamine has been largel

244 ore, astrocytes may be a possible target for hemorrhagic stroke prevention and therapy.

245 06; 95% CI, 2.62-3.57; P<0.001) and nonfatal hemorrhagic stroke rates (adjusted HR, 1.76; 95% CI, 1.0

246 imes higher in the age group 55 to 64 years; hemorrhagic stroke rates were 5 to 6 times (age <55 year

247 Hemorrhagic stroke rates were similar in both age groups

248 and a nonsignificant increase in the risk of hemorrhagic stroke (relative risk, 1.24; 95 percent conf

249 erval: 0.52, 0.83; p(trend) = 0.001) and for hemorrhagic stroke, relative risk = 0.51 (95% confidence

250 and whether loci influence both ischemic and hemorrhagic stroke, remains unknown.

251 1,256 and 164 persons developed ischemic and hemorrhagic stroke, respectively.

252 e of refined carbohydrate is associated with hemorrhagic stroke risk, particularly among overweight o

253 take was inversely associated with total and hemorrhagic stroke risk; for total stroke, relative risk

254 hest case volume (more than 50 patients with hemorrhagic stroke), risk-adjusted rates ranged from 8.0

255 In acute hemorrhagic stroke, SBP greater than 140 has been correl

256 Hemorrhagic stroke seemed to be more prevalent in the st

257 ption activity is a key pathogenic factor in hemorrhagic stroke, seizure activity, and central nervou

258 n the brain and are strongly associated with hemorrhagic stroke, seizures, and other neurological dis

259 he central nervous system that can result in hemorrhagic stroke, seizures, recurrent headaches, and f

260 ult rats were subjected to ischemic strokes, hemorrhagic strokes, sham surgeries, kainate-induced sei

261 The results were similar when ischemic and hemorrhagic stroke subtypes were considered separately.

262 Results were similar for ischemic and hemorrhagic stroke subtypes, for RBC fatty acids, and in

263 rove valuable for patients with ischemic and hemorrhagic stroke, such as earlier recognition, more ac

264 Aspirin increased the risk for hemorrhagic strokes (summary odds ratio, 1.4 [CI, 0.9 to

265 ditioning protocol and all patients but one (hemorrhagic stroke) survived through 1 year of follow-up

266 was the combined events of ischemic stroke, hemorrhagic stroke, systemic embolism, and cardiovascula

267 tion, or stroke, including both ischemic and hemorrhagic stroke (the latter being smaller in absolute

268 ute cognitive decline or seizure rather than hemorrhagic stroke, the primary clinical presentation in

269 For combined ischemic and hemorrhagic strokes, the intention-to-treat hazard ratio

270 ogical disorders, including ischemic stroke, hemorrhagic stroke, traumatic brain injury, Alzheimer's

271 myocardial infarction, ischemic stroke, and hemorrhagic stroke using DerSimonian and Laird random-ef

272 encephalomyelitis, meningitis, ischemic and hemorrhagic stroke, venous sinus thrombosis, and endothe

273 The rate of hemorrhagic stroke was 0.24% per year in the apixaban gr

274 7.7% (95% CI, 6.4-8.8%) in men; the risk of hemorrhagic stroke was 0.8% (95% CI, 0.4-1.2%) and 1.3%

275 irocumab treatment at month 4 and subsequent hemorrhagic stroke was assessed.

276 Hemorrhagic stroke was associated with low steady-state

277 The risk of nonfatal or fatal ischemic or hemorrhagic stroke was evaluated, stratified by baseline

278 Using autologous blood, hemorrhagic stroke was induced at specific coordinates i

279 Power to detect effects on hemorrhagic stroke was limited.

280 An increase in hemorrhagic stroke was not seen at low LDL-C levels.

281 o received thrombolytic therapy, the rate of hemorrhagic stroke was not significantly different for u

282 A reduction in hemorrhagic stroke was observed with rivaroxaban in pati

283 Hemorrhagic stroke was significantly less than ischemic

284 The incidence of hemorrhagic stroke was similar in the 80-mg and 10-mg gr

285 ease and cerebrovascular disease, especially hemorrhagic stroke, was higher in every Asian-American s

286 Rates of hemorrhagic stroke were 0.13% and 0.14%/y.

287 The pooled relative risks of hemorrhagic stroke were 2.24 (95% CI, 1.19-4.21) in wome

288 Associations of vitamin intake with hemorrhagic stroke were also nonsignificant, but the CIs

289 09 without a previous history of ischemic or hemorrhagic stroke were identified from Taiwan's Nationa

290 age, 79.6 years; 31 377 women [58.9%]) with hemorrhagic stroke were identified in the study period.

291 t rates were higher when ischemic stroke and hemorrhagic stroke were present (76% and 86%, respective

292 0-mg groups, 16 and 18 respectively, and the hemorrhagic strokes were distributed evenly across quint

293 Furthermore, 65% of hemorrhagic strokes were noted post-procedure and pre-di

294 intake was associated with elevated risk of hemorrhagic stroke when the extreme quintiles were compa

295 R: 1.94) were multivariable risk factors for hemorrhagic stroke, whereas female (HR: 1.84) and histor

296 odifiable risk factors for both ischemic and hemorrhagic stroke, while hypertension, smoking, diet, a

297 disorders including ischemic infarction and hemorrhagic stroke who are heterozygous for factor V Lei

298 ected associations were an increased risk of hemorrhagic stroke with lower sodium-to-potassium ratio

299 Men have an increased risk for hemorrhagic strokes with aspirin use.

300 major extracranial bleeding and ischemic or hemorrhagic stroke within 7 days after randomization.